These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 3095082)

  • 1. Safety evaluation of ritanserin--an investigational serotonin antagonist.
    Barone JA; Bierman RH; Cornish JW; Hsuan A; Drake ND; Colaizzi JL
    Drug Intell Clin Pharm; 1986 Oct; 20(10):770-5. PubMed ID: 3095082
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The influence of ritanserin, a serotonin antagonist, in anxiety disorders: a double-blind placebo-controlled study versus lorazepam.
    Ceulemans DL; Hoppenbrouwers ML; Gelders YG; Reyntjens AJ
    Pharmacopsychiatry; 1985 Sep; 18(5):303-5. PubMed ID: 3931107
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serotonin S2 receptors blockage and generalized anxiety disorders. A double-blind study on ritanserin and lorazepam.
    Bressa GM; Marini S; Gregori S
    Int J Clin Pharmacol Res; 1987; 7(2):111-9. PubMed ID: 3108171
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 5-HT2 receptor antagonism in dysthymic disorder: a double-blind placebo-controlled study with ritanserin.
    Bersani G; Pozzi F; Marini S; Grispini A; Pasini A; Ciani N
    Acta Psychiatr Scand; 1991 Apr; 83(4):244-8. PubMed ID: 1903019
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effects of the 5 HT2 antagonist ritanserin on blood pressure and serotonin-induced platelet aggregation in patients with untreated essential hypertension.
    Stott DJ; Saniabadi AR; Hosie J; Lowe GD; Ball SG
    Eur J Clin Pharmacol; 1988; 35(2):123-9. PubMed ID: 3142775
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Double-Blind, Placebo-Controlled Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single, Escalating Oral Doses of JDTic.
    Buda JJ; Carroll FI; Kosten TR; Swearingen D; Walters BB
    Neuropsychopharmacology; 2015 Aug; 40(9):2059-65. PubMed ID: 25628006
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evidence for serotonin-S2 receptor involvement in analgesia in humans.
    Sandrini G; Alfonsi E; De Rysky C; Marini S; Facchinetti F; Nappi G
    Eur J Pharmacol; 1986 Nov; 130(3):311-4. PubMed ID: 3098573
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of acute platelet thrombosis formation in stenosed canine coronary arteries by specific serotonin 5HT2 receptor antagonist ritanserin.
    Torr S; Noble MI; Folts JD
    Cardiovasc Res; 1990 Jun; 24(6):465-70. PubMed ID: 2117499
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 5-HT2 antagonist ritanserin in neuroleptic-induced parkinsonism: a double-blind comparison with orphenadrine and placebo.
    Bersani G; Grispini A; Marini S; Pasini A; Valducci M; Ciani N
    Clin Neuropharmacol; 1990 Dec; 13(6):500-6. PubMed ID: 2125857
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of ritanserin on sleep disturbances of dysthymic patients.
    Paiva T; Arriaga F; Wauquier A; Lara E; Largo R; Leitao JN
    Psychopharmacology (Berl); 1988; 96(3):395-9. PubMed ID: 3146774
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ritanserin as an adjunct to lithium and haloperidol for the treatment of medication-naive patients with acute mania: a double blind and placebo controlled trial.
    Akhondzadeh S; Mohajari H; Reza Mohammadi M; Amini H
    BMC Psychiatry; 2003 Jun; 3():7. PubMed ID: 12816549
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Does acute serotonergic type-2 antagonism reduce blood pressure? Comparative effects of single doses of ritanserin and ketanserin in essential hypertension.
    Hosie J; Stott DJ; Robertson JI; Ball SG
    J Cardiovasc Pharmacol; 1987; 10 Suppl 3():S86-8. PubMed ID: 2446081
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ritanserin in relapse prevention in abstinent alcoholics: results from a placebo-controlled double-blind international multicenter trial. Ritanserin in Alcoholism Work Group.
    Wiesbeck GA; Weijers HG; Chick J; Naranjo CA; Boening J
    Alcohol Clin Exp Res; 1999 Feb; 23(2):230-5. PubMed ID: 10069551
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Receptor-binding properties in vitro and in vivo of ritanserin: A very potent and long acting serotonin-S2 antagonist.
    Leysen JE; Gommeren W; Van Gompel P; Wynants J; Janssen PF; Laduron PM
    Mol Pharmacol; 1985 Jun; 27(6):600-11. PubMed ID: 2860558
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single-dose ritanserin and alcohol in healthy volunteers: a placebo-controlled trial.
    Estevez F; Parrillo S; Giusti M; Monti JM
    Alcohol; 1995; 12(6):541-5. PubMed ID: 8590616
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of ritanserin, a selective and specific S2-serotonergic antagonist, on portal pressure and splanchnic hemodynamics in portal hypertensive rats.
    Nevens F; Pizcueta MP; Fernández M; Bosch J; Rodés J
    Hepatology; 1991 Dec; 14(6):1174-8. PubMed ID: 1959867
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Down regulation of serotonin-S2 receptor sites in rat brain by chronic treatment with the serotonin-S2 antagonists: ritanserin and setoperone.
    Leysen JE; Van Gompel P; Gommeren W; Woestenborghs R; Janssen PA
    Psychopharmacology (Berl); 1986; 88(4):434-44. PubMed ID: 3010361
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ritanserin and serotonergic mechanisms in blood pressure and fluid regulation in sheep.
    Nelson M; Coghlan JP; Denton DA; Tresham JJ; Whitworth JA; Scoggins BA
    Clin Exp Pharmacol Physiol; 1987 Jul; 14(7):555-63. PubMed ID: 3124998
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative haemodynamic effects of ketanserin and ritanserin in the proximal and distal upper limb circulations of hypertensive patients.
    Chau NP; Pithois-Merli I; Levenson J; Simon AC
    Eur J Clin Pharmacol; 1989; 37(3):215-20. PubMed ID: 2533074
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomised double-blind 16-week study of ritanserin in fibromyalgia syndrome: clinical outcome and analysis of autoantibodies to serotonin, gangliosides and phospholipids.
    Olin R; Klein R; Berg PA
    Clin Rheumatol; 1998; 17(2):89-94. PubMed ID: 9641502
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.